NCT07522411 2026-04-13
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
Tongji Hospital
Phase 1/2 Not yet recruiting
Clinical Trials
102 trialsNCT07495215 2026-03-27
A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection
Sir Run Run Shaw Hospital
Phase 1/2 Recruiting
NCT05468359 2026-03-16
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT04380545 2026-03-06
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04785287 2026-03-03
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03942328 2026-02-24
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Mayo Clinic
Phase 1/2 Recruiting
NCT07410494 2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2 Recruiting
NCT03211416 2026-02-05
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT06923761 2026-01-28
EMITT-1
Grey Wolf Therapeutics
Phase 1/2 Recruiting
NCT03539822 2026-01-21
CAMILLA
University of Pittsburgh
Phase 1/2 Recruiting
NCT07282184 2025-12-18
Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
Tongji Hospital
Phase 1/2 Recruiting
NCT07187284 2025-09-22
EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial
Zhongda Hospital
Phase 1/2 Not yet recruiting
NCT05057013 2025-08-11
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
Cancer Research UK
Phase 1/2 Active not recruiting
NCT06294548 2025-08-11
A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
University of Alabama at Birmingham
Phase 1/2 Recruiting
NCT06695026 2025-07-29
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma
Rznomics, Inc.
Phase 1/2 Recruiting
NCT07075419 2025-07-20
JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure
West China Hospital
Phase 1/2 Not yet recruiting
NCT07042919 2025-06-29
Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
Northwestern University
Phase 1/2 Not yet recruiting
NCT06741020 2025-05-23
HAICI
Zhejiang Cancer Hospital
Phase 1/2 Recruiting
NCT06911255 2025-05-14
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Seoul National University Hospital
Phase 1/2 Recruiting
NCT01754987 2025-05-04
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
Thomas Jefferson University
Phase 1/2 Completed
NCT03397654 2025-03-06
PETAL
Imperial College London
Phase 1/2 Completed
NCT03190174 2025-02-17
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Sarcoma Oncology Research Center, LLC
Phase 1/2 Completed
NCT06725121 2024-12-16
MacroTrans
University Health Network, Toronto
Phase 1/2 Recruiting
NCT05595473 2024-11-04
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma
Rznomics, Inc.
Phase 1/2 Active not recruiting
NCT06641453 2024-10-16
CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma
Chinese PLA General Hospital
Phase 1/2 Not yet recruiting
NCT04170556 2024-09-03
GOING
Fundacion Clinic per a la Recerca Biomédica
Phase 1/2 Completed
NCT06006286 2024-08-26
A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT06463522 2024-08-13
Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma
Beijing 302 Hospital
Phase 1/2 Recruiting
NCT06527495 2024-07-30
Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
Assiut University
Phase 1/2 Recruiting
NCT05924997 2024-02-21
Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Recruiting
NCT05842317 2024-02-09
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT03867370 2023-11-29
Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Terminated
NCT06040177 2023-09-15
Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
First Affiliated Hospital of Guangxi Medical University
Phase 1/2 Unknown
NCT03695250 2023-08-22
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
University of California, Davis
Phase 1/2 Terminated
NCT05109052 2023-07-13
Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
University of Rochester
Phase 1/2 Withdrawn
NCT04631731 2023-06-01
ICEMELT
Western Sydney Local Health District
Phase 1/2 Unknown
NCT04652440 2023-04-19
Ablation Combined With PD-1 in HCC: Phase II Study
Sun Yat-sen University
Phase 1/2 Unknown
NCT04443309 2023-03-29
Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT04124991 2023-03-16
SOLID
Seoul National University Hospital
Phase 1/2 Completed
NCT03475953 2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2 Unknown
NCT04911959 2023-02-06
Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Unknown
NCT03648073 2023-01-10
[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
University of Alabama at Birmingham
Phase 1/2 Completed
NCT03682276 2022-12-13
PRIME-HCC
Imperial College London
Phase 1/2 Unknown
NCT03864211 2022-09-29
Thermal Ablation Followed by Immunotherapy for HCC
Xiangya Hospital of Central South University
Phase 1/2 Unknown
NCT03945799 2022-08-31
A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence
Zhejiang University
Phase 1/2 Terminated
NCT02575339 2022-07-26
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT02562963 2022-05-02
Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor
Tsinghua University
Phase 1/2 Unknown
NCT00867321 2022-04-19
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT05323201 2022-04-12
Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
The Affiliated Hospital of Xuzhou Medical University
Phase 1/2 Recruiting